Japanese Mergers Provide Opening For Biotech Deals - Novartis Licensing Head
This article was originally published in PharmAsia News
Recent mergers in the Japanese pharmaceutical market have provided U.S. and European biotechs enhanced opportunities to partner with Japanese pharmas looking to fill pipelines and compete globally, according to Novartis Global Head of Business Development and Licensing Anthony Rosenberg. However, Rosenberg cautioned that this same dynamic also could mean fewer opportunities for multinational pharmas to license compounds from their Japanese counterparts
You may also be interested in...
Firm is seeking approval of telavancin for complicated skin and skin structure infections caused by Gram-positive bacteria.
Establishment of the R&D site reflects Novartis’ commitment to the region, according to the drug maker.
Phase I compound AJD101 has a new mechanism of action that stimulates insulin independent glucose uptake in preclinical studies, according to the two Tokyo-based drug makers.